Oncology Central recently interviewed Dr Filippo Montemurro, Editorial Board member of Breast Cancer Management, Director of the Multidisciplinary Oncology Outpatient Clinic at the Fondazione del Piemonte per l’Oncologia/Candiolo Cancer Institute (IRCCS; Italy) and the coordinator of the Piedmont Oncology Network Breast Cancer Working Group (Italy). During his fellowship and his professional career, Montemurro has focused on breast cancer and biologically targeted therapies for the HER2-positive subset, where he has acquired competence and international visibility.
Montemurro, in collaboration with colleagues at the European Institute of Oncology in Milan, Italy, has first described differences in the clinical behavior and response to treatment in women with HER2-positive breast cancer according to co-expression of hormone receptors. He is Principal Investigator and steering committee member of a number of Phase II and III, multicentric international clinical trials in breast cancer. Furthermore, he co-chairs a special program in patients with metastatic cancer of unknown primary origin, which includes clinical and molecular investigations in this rare, but meaningful disease subset. Presently, Montemurro has published 157 papers in international medical journals, a substantial proportion of which as first, senior or corresponding author.
To view the full article, please register now for access